Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2

Conference Reports for NATAP

ID Week 2024
October 16-19
Los Angeles, California


Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2

	NATAP conference coverage HIVR4P 2024 5th HIV Research for Prevention Conference Oct 6-10 2024 Lima, Peru PURPOSE 1, Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women NEJM